Different Chemotherapeutic Scheme Plus Radiation for Inoperable Stage III Non-Small Cell Lung Cancer

尹先哲,郭伟,关红梅,杜峰,蔡勇
DOI: https://doi.org/10.3760/cma.j.issn.1008-6706.2001.04.005
2001-01-01
Abstract:Objective To evaluate the effect of different chemotherapeutic scheme plus radiation for inoperable stage Ⅲ non small cell lung cancer(NSCLC).Methods 57 patients with inoperadle stage Ⅲ NSCLC were randomly divided into two groups:29 patients received therapy with Paclitaxel(210 mg,dl),Cisplatin(20 mg,d1~5) for 2 cycles followed by radiotherapy(RT)(therapy groups).28 patients received Vp 16(100 mg,d1~5),Cisplatin(20 mg,d1~5) for 2 cycles followed by radiotherapy(control group).RT in both groups was similar,patients in conventional fractionation received 2 Gy/per fraction,five fractions/per week,with the total dose of 60~70 Gy to areas of primary and lymph node involvement and 40 Gy in regionally lymphatic drainage.Results The overall response rate in therapy group was 82.8%,with the complete response rate of 10.4%.The overall responce rate in the control group was 53.6%,and the complete response rate was 17.9%.The difference of overall response rates was statistically significant in both groups.The major toxic effects of chemotherapy were gastrointerstinal tract reaction nausea,vomiting and myelosuppression leukopenia.Conclusion PP chemotherapeutic scheme plus radiation for inoperable stage Ⅲ NSCLC is acceptable and the curative effect is superior to EP scheme plus radiation.
What problem does this paper attempt to address?